November 27, 2018
Salk scientists uncover how certain retinal cells respond to artificial illumination
LA JOLLA—For most, the time spent staring at screens—on computers, phones, iPads—constitutes many hours and can often disrupt sleep. Now, Salk Institute researchers have pinpointed how certain cells in the eye process ambient light and reset our internal clocks, the daily cycles of physiological processes known as the circadian rhythm. When these cells are exposed to artificial light late into the night, our internal clocks can get confused, resulting in a host of health issues.
The results, published November 27, 2018, in Cell Reports, may help lead to new treatments for migraines, insomnia, jet lag and circadian rhythm disorders, which have been tied to cognitive dysfunction, cancer, obesity, insulin resistance, metabolic syndrome and more.
“We are continuously exposed to artificial light, whether from screen time, spending the day indoors or staying awake late at night,” says Salk Professor Satchidananda Panda, senior author of the study. “This lifestyle causes disruptions to our circadian rhythms and has deleterious consequences on health.”
The backs of our eyes contain a sensory membrane called the retina, whose innermost layer contains a tiny subpopulation of light-sensitive cells that operate like pixels in a digital camera. When these cells are exposed to ongoing light, a protein called melanopsin continually regenerates within them, signaling levels of ambient light directly to the brain to regulate consciousness, sleep and alertness. Melanopsin plays a pivotal role in synchronizing our internal clock after 10 minutes of illumination and, under bright light, suppresses the hormone melatonin, responsible for regulating sleep.
“Compared to other light-sensing cells in the eye, melanopsin cells respond as long as the light lasts, or even a few seconds longer,” says Ludovic Mure, staff scientist and first author of the paper. “That’s critical, because our circadian clocks are designed to respond only to prolonged illumination.”
In the new work, the Salk researchers used molecular tools to turn on production of melanopsin in retinal cells in mice. They discovered that some of these cells have the ability to sustain light responses when exposed to repeated long pulses of light, while others become desensitized.
Conventional wisdom has held that proteins called arrestins, which stop the activity of certain receptors, should halt cells’ photosensitive response within seconds of lights coming on. The researchers were surprised to find that arrestins are in fact necessary for melanopsin to continue responding to prolonged illumination.
In mice lacking either version of the arrestin protein (beta arrestin 1 and beta arrestin 2), the melanopsin-producing retinal cells failed to sustain their sensitivity to light under prolonged illumination. The reason, it turns out, is that arrestin helps melanopsin regenerate in the retinal cells.
“Our study suggests the two arrestins accomplish regeneration of melanopsin in a peculiar way,” Panda says. “One arrestin does its conventional job of arresting the response, and the other helps the melanopsin protein reload its retinal light-sensing co-factor. When these two steps are done in quick succession, the cell appears to respond continuously to light.”
By better understanding the interactions of melanopsin in the body and how the eyes react to light, Panda hopes to find new targets to counter skewed circadian rhythms due to, for example, artificial illumination. Previously, Panda’s research team discovered that chemicals called opsinamides could block melanopsin’s activity in mice without affecting their vision, offering a potential therapeutic avenue to address hypersensitivity to light experienced by migraine sufferers. Next, the researchers aim to find ways to influence melanopsin to reset the internal clocks and help with insomnia.
Other authors include Salk postdoctoral researcher Megumi Hatori, now at Keio University School of Medicine in Tokyo; Kiersten Ruda and James Demas of St. Olaf College; and Salk former visiting graduate student Giorgia Benegiamo.
This work was supported by the Leona M. and Harry B. Helmsley Charitable Trust, the National Institutes of Health and the Glenn Foundation.
Ludovic S. Mure, Megumi Hatori, Kiersten Ruda, Giorgia Benegiamo, James Demas and Satchidananda Panda
Office of Communications
Tel: (858) 453-4100
Unlocking the secrets of life itself is the driving force behind the Salk Institute. Our team of world-class, award-winning scientists pushes the boundaries of knowledge in areas such as neuroscience, cancer research, aging, immunobiology, plant biology, computational biology and more. Founded by Jonas Salk, developer of the first safe and effective polio vaccine, the Institute is an independent, nonprofit research organization and architectural landmark: small by choice, intimate by nature and fearless in the face of any challenge.